Chronic neuroleptic therapy: tolerance and GABA systems.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000613:Aminobutyrates / Q000378:metabolism*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001921:Brain / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced; D002531:Cerebellum / Q000378:metabolism; D003024:Clozapine / Q000008:administration & dosage / Q000494:pharmacology; D003342:Corpus Striatum / Q000201:enzymology; D004298:Dopamine / Q000032:analysis; D004361:Drug Tolerance; D005968:Glutamate Decarboxylase / Q000378:metabolism; D006220:Haloperidol / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000032:analysis; D051381:Rats; D013378:Substantia Nigra / Q000378:metabolism; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D000613:Aminobutyrates; D014150:Antipsychotic Agents; D005680:gamma-Aminobutyric Acid; D005968:Glutamate Decarboxylase; D000262:Adenylyl Cyclases; D003024:Clozapine; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine